- Home
- CNC vs TEVA Comparison
CNC vs TEVA Comparison
Compare CNC & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNC | TEVA |
|---|---|---|
| Founded | 1984 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 37.1B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNC | TEVA |
|---|---|---|
| Price | $63.07 | $30.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $46.75 | $38.63 |
| AVG Volume (30 Days) | 2.9M | ★ 4.3M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $194,777,000,000.00 | N/A |
| Revenue This Year | $8.31 | N/A |
| Revenue Next Year | $1.05 | $2.97 |
| P/E Ratio | ★ $20.49 | $28.19 |
| Revenue Growth | ★ 19.44 | N/A |
| 52 Week Low | $25.08 | $14.99 |
| 52 Week High | $69.36 | $37.35 |
Technical Indicators
Market Signals| Indicator | CNC | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 40.73 |
| Support Level | $63.20 | $30.59 |
| Resistance Level | $69.32 | $32.74 |
| Average True Range (ATR) | 2.24 | 0.97 |
| MACD | -0.68 | -0.19 |
| Stochastic Oscillator | 5.54 | 23.56 |
Price Performance
Historical ComparisonAbout CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.